Economic information and modeling report
Modeling overview
16 evidence topics · 12 sources
Summary
No economic model, cost-effectiveness analysis, budget impact analysis, or health technology assessment of lonimecgene renparvovec (TSHA-102) was identified, and Taysha Gene Therapies has announced no price. Taysha estimates an addressable population of 15,000 to 20,000 patients with typical Rett syndrome caused by a pathogenic or likely pathogenic MECP2 mutation in the United States, the European Union, and the United Kingdom. In its second quarter 2026 results announcement, the company reported completed payer research in which TSHA-102 was viewed as a high-value therapy, with durable functional benefit as the key value determinant; its annual report states that the reimbursement structure of other companies' approved gene therapies could affect the anticipated reimbursement structure of its own products.
Trofinetide (DAYBUE) was approved by the FDA in March 2023 for the treatment of Rett syndrome. Acadia stated a list price of $21.10 per mL, or an estimated average net realized cost to payers of about $375,000 per year. Net product sales of DAYBUE were $177.2 million in 2023, $348.4 million in 2024, and $391.4 million in 2025. In a real-world analysis, 766 of 2,950 eligible individuals (26.0%) initiated trofinetide in the early post-approval period.
Canada's Drug Agency (CDA-AMC) appraised the sponsor's cost-effectiveness and budget impact analyses for trofinetide, and amounts below are those reported in that review. The sponsor's Markov cost-utility model, with 4 health states defined by Rett Syndrome Behaviour Questionnaire (RSBQ) score plus death and a lifetime horizon of 79.1 years, produced an incremental cost-effectiveness ratio of $5,864,321 per quality-adjusted life-year (QALY) gained (incremental costs $3,386,675; incremental QALYs 0.578), and a price reduction of more than 98% would be required to meet a threshold of $100,000 per QALY gained. Health state utilities, from a discrete choice experiment commissioned to develop utility-based scoring weights for the RSBQ, ranged from 0.6409 (mild to moderate) to 0.2160 (very severe). The sponsor's budget impact analysis, from the perspective of the pan-Canadian drug plans, assumed 95, 21, and 22 patients would start publicly reimbursed trofinetide in years 1, 2, and 3; the CDA-AMC reanalysis estimated a 3-year incremental budgetary cost of $166,461,725, with scenario analyses up to $333 million, and CDA-AMC recommended that trofinetide not be reimbursed by public drug plans. A systematic literature review screened 221 unique citations for pharmacoeconomic models and found no eligible publication.
Published economic model of TSHA-102
No evidence found.
Cost-effectiveness or budget impact analysis of TSHA-102
No evidence found.
Health technology assessment of TSHA-102
No evidence found.
Announced price or pricing guidance for TSHA-102
No evidence found.
Company estimate of the addressable population
Company statements on market opportunity and site of care, June 2026
Company payer research, August 2026
Company market access leadership with gene therapy experience
Company statements on reimbursement precedent of other gene therapies
Trofinetide: United States list price and estimated net cost at launch
Trofinetide: United States net product sales, 2023 to 2025
Trofinetide: uptake in United States claims after approval
“Of 8047 individuals with RTT identified, 2950 met eligibility criteria; 766 (26.0%) were treated with TROF and 2184 (74.0%) remained untreated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this real-world analysis, only one-quarter of eligible individuals with RTT initiated TROF during the early post-approval period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote